Cargando…
Corrections to “Phase III trial of nonpegylated liposomal doxorubicin in combination with trastuzumab and paclitaxel in HER2-positive metastatic breast cancer”
Autores principales: | Baselga, J., Manikhas, A., Cortés, J., Llombart, A., Roman, L., Semiglazov, V.F., Byakhov, M., Lokanatha, D., Forenza, S., Goldfarb, R.H., Matera, J., Azarnia, N., Hudis, C.A., Rozencweig, M. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7340185/ https://www.ncbi.nlm.nih.gov/pubmed/30624616 http://dx.doi.org/10.1093/annonc/mdy529 |
Ejemplares similares
-
Substituting Doxorubicin with Nonpegylated Liposomal Doxorubicin for the Treatment of Early Breast Cancer: Results of a Retrospective Study
por: Davidson, Neville, et al.
Publicado: (2014) -
Corrigendum: Photothermal therapeutic application of gold nanorods-porphyrin-trastuzumab complexes in HER2-positive breast cancer
por: Kang, Xinmei, et al.
Publicado: (2017) -
“Short Course” of Nonpegylated Liposomal Doxorubicin Plus Paclitaxel and Trastuzumb as Primary Systemic Therapy for Operable and Locally-Advanced Breast Cancer: A Phase II Study (PacLiDox 07)
por: Rossi, D., et al.
Publicado: (2011) -
Corrections to “Pooled analysis of cardiac safety in patients with cancer treated with pertuzumab”
por: Lenihan, D., et al.
Publicado: (2019) -
3rd ESO–ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 3)
por: Cardoso, F, et al.
Publicado: (2017)